Re­genxbio opens gene ther­a­py man­u­fac­tur­ing fa­cil­i­ty at its Mary­land HQ

Re­genxbio is push­ing deep­er in­to the gene ther­a­py space with the open­ing of a new fa­cil­i­ty at its cam­pus in the Wash­ing­ton D.C., sub­urb of Rockville, MD.

Built in a year, the $65 mil­lion, 132,000-square-foot GMP fa­cil­i­ty will en­able the com­pa­ny to boost its man­u­fac­tur­ing of NAV Tech­nol­o­gy-based ade­no-as­so­ci­at­ed virus, or AAV, vec­tors at scales up to 2,000 liters. The fa­cil­i­ty will al­so im­ple­ment Re­genxbio’s plat­form sus­pen­sion cell cul­ture process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER